



(51) International Patent Classification:

A61K 31/4748 (2006.01) **A61P 25/00** (2006.01)
A61K 31/5386 (2006.01) **A61P 29/00** (2006.01)
A61P 1/16 (2006.01) **A61P 35/00** (2006.01)
A61P 3/00 (2006.01) **A61P 43/00** (2006.01)
A61P 7/06 (2006.01) **C07D 471/18** (2006.01)
A61P 9/00 (2006.01) **C07D 491/22** (2006.01)
A61P 11/00 (2006.01) **C07D 498/18** (2006.01)
A61P 13/12 (2006.01) **C07D 498/22** (2006.01)

(21) International Application Number:

PCT/JP2019/048593

(22) International Filing Date:

04 December 2019 (04.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2018-228234 05 December 2018 (05.12.2018) JP

(71) Applicant: **SCOHIA PHARMA, INC.** [JP/JP]; 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP).


(72) Inventors: **MATSUMOTO, Shigemitsu**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fu-

jisawa-shi, Kanagawa, 2518555 (JP). **HARA, Ryoma**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **NOGUCHI, Naoyoshi**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **FUKUSHI, Hideto**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **NIIDA, Ayumu**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **SASAKI, Satoshi**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **IKOMA, Minoru**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **KOBAYASHI, Toshitake**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP). **MAEKAWA, Tsuyoshi**; c/o SCOHIA PHARMA, INC., 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, 2518555 (JP).

(74) Agent: **KOBAYASHI, Hiroshi** et al.; ABE, IKUBO & KATAYAMA, Fukuoka Bldg. 9th Fl., 8-7, Yaesu 2-chome, Chuo-ku, Tokyo, 1040028 (JP).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: MACROCYCLIC COMPOUND AND USE THEREOF



(57) Abstract: A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.



CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))